Lamivudine NEW
| Price | $53 | $79 | $189 |
| Package | 50mg | 100mg | 500mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Lamivudine | CAS No.: 134678-17-4 |
| Purity: 99.56% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Lamivudine |
| Description | Lamivudine (BCH-189) is a reverse transcriptase inhibitor and ZALCITABINE analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat HIV disease. |
| In vivo | Lamivudine exhibits selective inhibitory activity against deoxycytidine kinase, an unusual substrate for the non-natural L-isomer of dNTPs preferred by HBV polymerase. The anti-HBV activity of PCV is attributed to the broad substrate specificity of deoxycytidine kinase and an unusual substrate preference of HBV polymerase for the non-natural L-conformation of dNTPs. The anti-HBV efficacy of PCV appears to rely on multiple factors, including optimal phosphorylation (sufficient for antiviral activity but not cytotoxicity), the extended intracellular half-life of PCV-TP, and the ability of PCV-TP to inhibit the initiation of HBV RT as well as its RT and DNA polymerase activities. Combined use of Lamivudine and Cidofovir synergistically inhibits replication of duck hepatitis B virus and is more effective in reducing the persistent covalently closed circular (CCC) DNA form of DHBV than when used separately. In PBMCs, Lamivudine inhibits HIV-1 p24 antigen production with ED50s ranging from 0.07 μM to 0.2 μM. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (239.9 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 42 mg/mL (183.2 mM) |
| Keywords | Human immunodeficiency virus | Hepatitis B virus | susceptible | Reverse Transcriptase | Lamivudine | HIV neurodegeneration | HBV | HIV | orally active | BCH 189 | CNS penetration,brain region | BCH189 | Inhibitor | inhibit |
| Inhibitors Related | Stavudine | Emtricitabine |
| Related Compound Libraries | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $53.00/50mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2024-11-01 | |
| $10.00/1kg |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-09 | |
| $10.00/1kg |
VIP1Y
|
Hebei Ganmiao New material Technology Co., LTD
|
2024-06-07 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-08 | |
| $35.00/1kg |
VIP1Y
|
Sigma Audley
|
2024-03-15 | |
| $185.00/1Kg/Bag |
VIP4Y
|
Sinoway Industrial co., ltd.
|
2023-12-15 | |
| $200.00/1kg |
Hebei Mingeng Biotechnology Co., Ltd
|
2022-11-20 | ||
| $10.00/1kg |
Hebei Linwo New Material Technology Co., LTD
|
2022-07-04 | ||
| $25.00/25KG |
XINGTAI XINGJIU NEW MATERIAL TECHNOLOGY CO., LTD
|
2021-12-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY